|
|
Vaccine Detail
|
Natural Killer Cells ZRx101 Vaccine |
| Vaccine Information |
- Vaccine Name: Natural Killer Cells ZRx101 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007023
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IL12
gene engineering:
- Preparation: (Vivier et al., 2008)
- Description: This is for Leukemia Cancer and Lymphoma Cancer(NCT00900809). A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT_C85466; Vivier et al., 2008)
|
| Host Response |
|
|
| References |
NCIT_C85466: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466]
NCT00900809: [https://clinicaltrials.gov/show/NCT00900809/]
Vivier et al., 2008: Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature immunology. 2008; 9(5); 503-510. [PubMed: 18425107].
|
|
